Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...
Breakthrough cancer trial offers hope for pancreatic cancer patients
Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...
Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer
These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) ...
News Medical20d
Combination of RAS inhibition and immunotherapy provides breakthrough for pancreatic cancer
These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...
Vividion Therapeutics, Inc.: Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Ka Inhibitor for Treatment of Advanced Solid Tumors
VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...